Top Markets
#1 Islamic Coin Islamic Coin +154.47%
#2 PulseChain PulseChain +49.22%
#3 RedStone RedStone +22.21%
#4 BOOK OF MEME BOOK OF MEME +18.12%
#5 Starpower Starpower +14.19%
#6 Venom Venom +12.35%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +12.28%
#8 Lighter Lighter +12.26%
#9 Nockchain Nockchain +11.12%
#10 SkyAI SkyAI +10.56%
Coin of the day
Islamic Coin Islamic Coin
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Biocartis Group N.V. Biocartis Group N.V.

Biocartis Group N.V.

BCART
Rang în acțiuni #27531
Biocartis Group NV is a molecular diagnostics firm dedicated to improving... Biocartis Group NV is a molecular diagnostics firm dedicated to improving clinical care. Its innovative diagnostic solutions primarily serve the oncology sector, benefiting patients, medical professionals, insurers, and the broader healthcare ecosystem. The company's cornerstone is its exclusive Idylla molecular diagnostics platform, a sophisticated real-time polymerase chain reaction (PCR) system. This technology delivers crucial molecular data, aiding in the selection of appropriate treatments and the continuous monitoring of patient progress. Biocartis offers a range of diagnostic tests via the Idylla system, including mutation analysis for BRAF, KRAS, MSI, EGFR, and NRAS-BRAF. Additionally, it provides Idylla panels for SARS-CoV-2/Flu/RSV, standalone SARS-CoV-2 tests, and the rapid host-response assessment, SeptiCyte RAPID. For research purposes, the company supplies various mutation assays, such as those for MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R. Biocartis has entered into strategic partnerships to broaden its impact. One such collaboration is with Amgen, focusing on evaluating Idylla RAS testing to enable swift, decentralized diagnostics and enhance the accessibility of RAS biomarker data through the Idylla platform and its associated RAS tests. Another key alliance is with Bristol-Myers Squibb Company, centered on the registration and application of the Idylla MSI test within the field of immuno-oncology treatments. Furthermore, a licensing, development, and commercialization agreement with GeneproDx is in place for the creation of the innovative ThyroidPrint genomic test, to be integrated onto the Idylla platform. Established in 2007, Biocartis maintains its corporate headquarters in Mechelen, Belgium.
Preț acțiune
$0.343985
Ultima sincronizare: 2024-07-23
Capitalizare de piață
$32.31M
Schimbare (1 zi)
11.88%
Schimbare (1 an)
0.00%
Țară
BE
Tranzacționează Biocartis Group N.V. (BCART)

Categorie

Healthcare
Istoricul spliturilor pentru Biocartis Group N.V. (BCART)
Acțiunea Biocartis Group N.V. (simbol: BCART) a trecut printr-un total de 0 splituri.
Cel mai recent split a avut loc pe Aug 20, 2026.
O acțiune BCART cumpărată înainte de Aug 20, 2026 este echivalentă astăzi cu 0 acțiuni BCART.
Listă splituri acțiuni
An Split Multiplu Multiplu cumulativ
Nu sunt suficiente date pentru perioada selectată.
Splituri pentru companii similare sau competitori
Companie Număr total de splituri Multiplu cumulativ Țara
Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
TMO.US
 8 x34
US
Danaher Corporation Danaher Corporation
Danaher Corporation
DHR.US
 7 x47
US
WuXi AppTec Co., Ltd. WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd.
603259.SS
 0 -
CN
Natera, Inc. Natera, Inc.
Natera, Inc.
NTRA.US
 0 -
US
IDEXX Laboratories, Inc. IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
IDXX.US
 4 x15
US